Health of women with cystic fibrosis during pregnancy and their young children
Official title: An Observational Study to Evaluate the Impact of Pregnancy and Parenthood in Females With Cystic Fibrosis and Their Offspring in the CFTR Modulator Era.
Run by Royal Brompton & Harefield NHS Foundation Trust · NCT06797206 · Data updated 2026-11-12
This project will follow women with cystic fibrosis who are planning pregnancy, pregnant, or new parents, and their babies to see how pregnancy and current CF treatments affect maternal physical and mental health and early child health.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | June 12, 2025 |
| Main results expected | April 2028 |
| Study ends | May 2028 |
| Registry record updated | October 1, 2025 |
| Trial ID | NCT06797206 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 16 or older with confirmed cystic fibrosis who are planning pregnancy or currently pregnant and under Royal Brompton care, and biological offspring (0–6 years) of parents with CF under Royal Brompton care.
✕Probably not a fit
People not followed at Royal Brompton, those not pregnant or planning pregnancy, or children outside the enrolled age windows are unlikely to directly benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
MATRIARCH_CF is an observational cohort that follows people with cystic fibrosis through pregnancy and early parenthood and follows their offspring in early life. It comprises three linked sub-studies: 'Mama' (pregnant or planning pregnancy, age 16+), 'Mini' (infants from birth to age 2), and 'Midi' (children age 3–6). Participants undergo scheduled in-person visits for blood tests, lung function, imaging, sweat tests, interviews, and other age-appropriate investigations such as brain ultrasound or lung MRI. The study does not provide experimental treatments but collects detailed health and psychosocial data to inform care models and screening recommendations in the CFTR modulator era.
Why it matters
Potential benefit: If successful, the study could inform clinical guidelines and improve monitoring and care for pregnant people with CF and their children.
How similar studies have gone: Previous observational cohorts have reported pregnancy outcomes in CF, but thorough early-childhood follow-up in the era of CFTR modulators remains limited, so this work is partly novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 'Mama' sub-study: * Written informed consent obtained from participant. * Under the care of Royal Brompton Hospital CF Reproductive and Maternal Health Service * Age 16 years or above at time of recruitment * Confirmed diagnosis of CF * Planning a pregnancy or pregnant at time of recruitment. * Ability to adhere to the required visits and investigations. 'Mini' sub-study: * Written informed consent obtained from participant's legal guardian. * Infants who have one biological parent with a confirmed diagnosis of CF under care of Royal Brompton Hospital Adult CF Service * Less than 12 months of age at first visit. * Ability to adhere to the required visits and investigations. 'Midi' sub-study: * Written informed consent obtained from participant's legal guardian. * Children who have one biological parent with a confirmed diagnosis of CF who is under the care of Royal Brompton Hospital Adult CF Service. * Age three to six years at time of visit * Ability to adhere to the required visits and investigations. Exclusion Criteria: 'Mama' sub-study: * Any significant health condition which would cause inability to comply with protocol based on investigator discretion. * History of lung transplantation 'Mini' sub-study: * Legal guardians' inability to provide consent to participate in the study. * Mother of infant has significant comorbidities unrelated to CF which could affect infant outcomes based on investigator discretion. 'Midi' sub-study: * Legal guardians' inability to provide consent to participate in the study. * A significant health condition which is known to affect lung function or imaging based on investigator discretion
Where it's running
-
Royal Brompton Hospital
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Imogen Felton — Royal Brompton Hospital and NHLI Imperial College London
- Study coordinator: Amy Downes
- Email: a.downes@imperial.ac.uk
- Phone: 020 7352 8121
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Restore a newborn's gut microbiota using the mother's microbes.
This will test whether giving C-section newborns bacteria from their own mother or commercial probiotics helps their gut microbiota become more like babies born vaginally.
-
Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide
This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.
-
Pelvic Floor Training and a Modified Lumbopelvic Belt for Symphysis Pubis Pain in Pregnancy
This study tests whether pelvic floor muscle training plus a modified lumbopelvic belt can reduce pain and improve function for pregnant women with symphysis pubis pain.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
Oropharyngeal suction and physiotherapy to detect lung bacteria in kids with chronic lung disease
A randomized study will test whether taking samples from the throat with suction, with or without prior physiotherapy, can reliably detect bacteria in children 5–18 with chronic lung disease, compared with standard sample methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.